AlphAIAlphAI — Financial news for AI agents
tipranks.comSEP 231 min read$ACIU

AC Immune Posts Strong Week-100 Phase 2 Data for Parkinson’s Vaccine ACI-7104

AC Immune (ACIU) reported positive week-100 data from Part 1 of its Phase 2 trial for Parkinson's vaccine ACI-7104, meeting safety, tolerability, and immunogenicity endpoints. All patients showed an antibody response, with data suggesting target engagement. The company plans to extend Part 1 and finalize Part 2 design to test clinical efficacy.

Original reporting
tipranks.com
Published Sep 23, 2026, 11:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 12:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AC Immune Posts Strong Week-100 Phase 2 Data for Parkinson’s Vaccine ACI-7104 — source image
Source · tipranks.com
Decision brief

The 30-second read

$ACIUBullishHigh
01

Why it matters

The week‑100 data confirms target engagement, a key step before expanding the trial.

02

Market read

First report of strong Phase 2 data likely to move the stock and influence sector sentiment.

03

What to watch

Regulatory pathway and long‑term safety still uncertain.

Relevance 8/10Novelty 8/10Timing: today

Background

AC Immune SA is a Swiss biotech developing immunotherapy vaccines for neurodegenerative diseases.

Company-level read

Ticker impact

$ACIUBullishHigh confidence
Context

AC Immune reported Phase 2 week‑100 data showing 100% antibody response and CSF penetration.

Expected impact

upward pressure in near‑term trading

Evidence & confidence

First disclosure of robust immunogenicity results; investors typically reward such milestones.

Market effects

Sector

strengthens neuro‑degeneration biotech sector outlook

Regional

potentially lifts European biotech sentiment

Global

adds to pipeline optimism for Parkinson's disease therapies

Counterpoint

What could challenge this read

Data may not translate to clinical efficacy; caution on over‑optimism.

Key entities

  • company
    AC Immune SA

    Biotech firm developing ACI‑7104 vaccine for Parkinson's disease.

Read at source← All news

Also covered by

3 outlets

Related articles

SEP 24
$ACIUMedAI 8/10

AC Immune says ACI-7104 shows durable immunogenicity

AC Immune (ACIU) reported positive safety and immunogenicity results for ACI-7104 in a Phase II trial for Parkinson's disease. The study's Part 1 involved 34 patients, with 25 receiving ACI-7104. Shares rose 3.7% to $2.83 on the news. The trial aims to assess safety, tolerability, and immunogenicity in Part 1, and clinical activity in Part 2.

thepharmaletter.com1 min
SEP 23
$ACIUHighAI 9/10

AC Immune reports positive phase 2 trial results for ACI-7104

AC Immune (ACIU) reported positive phase 2 trial results for ACI-7104 in early-stage Parkinson’s disease. All 25 patients developed antibodies, with the treatment being safe and well-tolerated. The trial continues with a two-year extension and plans for Part 2. ACI-7104 targets alpha-synuclein protein aggregates, and the company has partnerships worth $4.5B in potential milestones.

investing.com2 min
AUG 20
$ACIUMedAI 8/10

AC Immune stock gains on early Phase 1 trial results

AC Immune SA (ACIU) shares rose 3.9% premarket after reporting positive Phase 1 trial data for ACI-19764, an NLRP3 inhibitor. The drug was safe, well-tolerated, and showed brain penetration. Phase 1b results are expected by year-end, with full results in 2027. ACI-19764 targets chronic inflammation in various diseases.

investing.com2 min